


	☐ Meliodosis (<i>Burkholderia</i> pseudomallei)	☐ Viral hemorrhagic fevers (<i>filoviruses</i> and <i>arenaviruses</i>)
	☐ Influenza	☐ Water Safety Threats (e.g., <i>Vibrio cholerae</i> , <i>Cryptosporidium parvum</i>)
	☐ Plague (<i>Yersinia pestis</i>)	☐ Other (Please Specify)
	☐ Psittacosis (<i>Chlamydia psittaci</i>)	
Technology Readiness Level Technology Readiness Level Descriptions		
Route of Administration	Check All	Uncheck All
	□ Intravenous	☐ Oral
	☐ Intramuscular Injection	☐ Subcutaneous
	☐ "Needle-Free" Injection	☐ Transdermal
	□ Intranasal	☐ Other (Please Specify)
Indications for Use (check all	Check All	Uncheck All
that apply)	☐ Pre-Exposure Prophylaxis	☐ Other (Please Specify)
	☐ Post-Exposure Prophylaxis	
Number of Doses Required for Efficacy or per Regimen		
Anticipated Product Stability	Years Months	
Temperature at which product is stable (please indicate range)		
Upload Documents		
	Refresh Documents	
*Does your submission include proprietary, confidential, or trade secret information?	○ No ○ Yes	
Please select those federal	Check All	Uncheck All
entities that you would be interested in potentially meeting	✓ HHS/BARDA	☑ HHS/FDA



Website Disclaimers | USA.gov | No Fear Act | Accessibility | Privacy Policy | White House | FOIA
This is an official U.S. Government Web site managed by the U.S. Department of Health & Human Services.

Contact Webmaster